C Laverdiere
Overview
Explore the profile of C Laverdiere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shalmiev A, Nadeau G, Aaron M, Ouimet-Grennan E, Drouin S, Bertout L, et al.
Pharmacogenomics J
. 2021 Aug;
22(1):19-24.
PMID: 34446917
Background: A substantial number of survivors of childhood acute lymphoblastic leukemia (ALL) suffer from treatment-related late adverse effects. While multiple studies have identified the effects of chemotherapeutics and radiation therapy...
2.
Beaulieu-Gagnon S, Belanger V, Meloche C, Curnier D, Sultan S, Laverdiere C, et al.
BMC Nutr
. 2020 Mar;
5:52.
PMID: 32153965
Background: Changes in food intake are common in children with cancer and are often caused by nausea and perturbations in sense of taste. The VIE (Valorization, Implication, Education) study proposes...
3.
Gatineau-Sailliant S, Glisovic S, Gagne V, Laverdiere C, Leclerc J, Silverman L, et al.
Leuk Res
. 2019 Oct;
86:106228.
PMID: 31590117
No abstract available.
4.
Delvin E, Marcil V, Alos N, Laverdiere C, Sinnett D, Krajinovic M, et al.
Clin Nutr ESPEN
. 2019 May;
31:28-32.
PMID: 31060831
Background: Treatment of childhood acute lymphoblastic leukemia (cALL) has reached unprecedented success leading to survival rates reaching 90%. This is regrettably linked to increased risk of developing long-term health-related sequels...
5.
Delvin E, Alos N, Rauch F, Marcil V, Morel S, Boisvert M, et al.
Clin Nutr
. 2018 Mar;
38(2):912-919.
PMID: 29503055
Background: The remarkable progress in the treatment of childhood acute lymphoblastic leukemia (cALL) has led to a survival rate reaching 90%. This success story is unfortunately linked to increased risk...
6.
Athale U, Mizrahi T, Laverdiere C, Nayiager T, Delva Y, Foster G, et al.
Pediatr Blood Cancer
. 2018 Jan;
65(5):e26938.
PMID: 29334169
Background: Children with acute lymphoblastic leukemia (ALL) have increased risk of thromboembolism (TE). However, the predictors of ALL-associated TE are as yet uncertain. Objective: This exploratory, prospective cohort study evaluated...
7.
Sulis M, Blonquist T, Stevenson K, Hunt S, Kay-Green S, Athale U, et al.
Pediatr Blood Cancer
. 2018 Jan;
65(5):e26952.
PMID: 29319209
Background: Pediatric patients receiving induction chemotherapy for newly diagnosed acute lymphoblastic leukemia (ALL) are at high risk of developing life-threatening infections. We investigated whether uniform antibacterial guidelines, including mandatory antibacterial...
8.
Pepin A, Lippe S, Krajinovic M, Laverdiere C, Michon B, Sinnett D, et al.
Pediatr Hematol Oncol
. 2017 Sep;
34(3):133-137.
PMID: 28922050
Objectives: Recent guidelines recommend to assess emotional distress in pediatric oncology during treatment and in after care. One tool used to do this is the distress thermometer (DT), a simple...
9.
Glisovic S, Pastore Y, Gagne V, Plesa M, Laverdiere C, Leclerc J, et al.
Pharmacogenomics J
. 2017 May;
18(2):270-274.
PMID: 28534526
Neutropenia and infection are major dose-limiting side effects of chemotherapy. The risk of initial infection and subsequent complications are directly related to the depth and duration of neutropenia. Recent genome-wide...
10.
Krajinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, Ansari M, et al.
Pharmacogenomics J
. 2016 Dec;
17(1):107.
PMID: 27958382
No abstract available.